Novabio Therapeutics Secures Tens of Millions in Pre-A Financing to Advance Treg Cell Therapy Development

Investment Circle (ID: pedaily2012) October 18 News: Shanghai Saierxin Biomedical Technology Co., Ltd. (hereinafter referred to as "NOVABIOTX")Completed a Pre-A round of financing worth tens of millions of RMB. This round of financing was jointly completed by Zeyu Capital and Semir Venture Capital.The proceeds from the financing will be mainly used to advance the clinical trials of the NP001 project and support the research and development of other products in the pipeline, with the aim of accelerating the clinical translation and commercialization process of Treg therapy.

NOVABIOTX has always been committed to the development of Treg cell therapy drugs. With a fully independent and innovative Treg pipeline layout, an experienced management team, and several key R&D projects advancing rapidly, it has become an important force in the field of Treg drug research and development. Compared with traditional Treg research approaches, NOVABIOTX's development strategy is more highlighted and advantageous, bringing more treatment options to patients with neurodegenerative diseases and autoimmune diseases.

Currently, NOVABIOTX has four Treg cell therapy drugs under development. The NP001 project is the most advanced, having already received ethical approval for investigator-initiated (IIT) clinical trials from the First Affiliated Hospital of Zhengzhou University. Meanwhile, CMC development and non-clinical studies that meet IND submission requirements are nearing completion, with plans to file an IND application with the U.S. FDA and China’s NMPA by the end of this year. The targeted Treg product NC001 is expected to confirm its candidate molecule by the end of this year, entering the formal CMC development phase early next year. The allogeneic NP005 project is also being developed concurrently.